Oculopharyngeal Muscular Dystrophy (OPMD) Market, Global Outlook and Forecast 2022-2028
Oculopharyngeal muscular dystrophy (OPMD) is a rare genetic muscle disorder with onset during adulthood most often between 40 and 60 years of age. OPMD is characterized by slowly progressive muscle disease (myopathy) affecting the muscles of the upper eyelids and the throat.
This report contains market size and forecasts of Oculopharyngeal Muscular Dystrophy (OPMD) in global, including the following market information:
Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Oculopharyngeal Muscular Dystrophy (OPMD) companies in 2021 (%)
The global Oculopharyngeal Muscular Dystrophy (OPMD) market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Tablets Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Oculopharyngeal Muscular Dystrophy (OPMD) include Benitec Biopharma Inc., Bioblast Pharma, BioMarin, PTC Therapeutics, NS Pharma, Nobelpharma Co., Ltd, Santhera Pharmaceuticals, Pfizer Inc. and Marathon Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Oculopharyngeal Muscular Dystrophy (OPMD) manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Oculopharyngeal Muscular Dystrophy (OPMD) Market, By Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Segment Percentages, By Type, 2021 (%)
Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Segment Percentages, By Application, 2021 (%)
Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Segment Percentages, By Region and Country, 2021 (%)
The report also provides analysis of leading market participants including:
Key companies Oculopharyngeal Muscular Dystrophy (OPMD) revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Oculopharyngeal Muscular Dystrophy (OPMD) revenues share in global market, 2021 (%)
Key companies Oculopharyngeal Muscular Dystrophy (OPMD) sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Oculopharyngeal Muscular Dystrophy (OPMD) sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
This report contains market size and forecasts of Oculopharyngeal Muscular Dystrophy (OPMD) in global, including the following market information:
Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Oculopharyngeal Muscular Dystrophy (OPMD) companies in 2021 (%)
The global Oculopharyngeal Muscular Dystrophy (OPMD) market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Tablets Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Oculopharyngeal Muscular Dystrophy (OPMD) include Benitec Biopharma Inc., Bioblast Pharma, BioMarin, PTC Therapeutics, NS Pharma, Nobelpharma Co., Ltd, Santhera Pharmaceuticals, Pfizer Inc. and Marathon Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Oculopharyngeal Muscular Dystrophy (OPMD) manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Oculopharyngeal Muscular Dystrophy (OPMD) Market, By Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Segment Percentages, By Type, 2021 (%)
- Tablets
- Capsules
- Injectable
- Other
Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Segment Percentages, By Application, 2021 (%)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
The report also provides analysis of leading market participants including:
Key companies Oculopharyngeal Muscular Dystrophy (OPMD) revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Oculopharyngeal Muscular Dystrophy (OPMD) revenues share in global market, 2021 (%)
Key companies Oculopharyngeal Muscular Dystrophy (OPMD) sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Oculopharyngeal Muscular Dystrophy (OPMD) sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Benitec Biopharma Inc.
- Bioblast Pharma
- BioMarin
- PTC Therapeutics
- NS Pharma
- Nobelpharma Co., Ltd
- Santhera Pharmaceuticals
- Pfizer Inc.
- Marathon Pharmaceuticals
- Fibrogen
- Bristol-Myers Squibb
- Sarepta Therapeutics
- GSK
1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS
1.1 Oculopharyngeal Muscular Dystrophy (OPMD) Market Definition
1.2 Market Segments
1.2.1 Market By Type
1.2.2 Market By Application
1.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 GLOBAL OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD) OVERALL MARKET SIZE
2.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size: 2021 VS 2028
2.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, Prospects & Forecasts: 2017-2028
2.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales: 2017-2028
3 COMPANY LANDSCAPE
3.1 Top Oculopharyngeal Muscular Dystrophy (OPMD) Players in Global Market
3.2 Top Global Oculopharyngeal Muscular Dystrophy (OPMD) Companies Ranked by Revenue
3.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Companies
3.4 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Companies
3.5 Global Oculopharyngeal Muscular Dystrophy (OPMD) Price by Manufacturer (2017-2022)
3.6 Top 3 and Top 5 Oculopharyngeal Muscular Dystrophy (OPMD) Companies in Global Market, by Revenue in 2021
3.7 Global Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Product Type
3.8 Tier 1, Tier 2 and Tier 3 Oculopharyngeal Muscular Dystrophy (OPMD) Players in Global Market
3.8.1 List of Global Tier 1 Oculopharyngeal Muscular Dystrophy (OPMD) Companies
3.8.2 List of Global Tier 2 and Tier 3 Oculopharyngeal Muscular Dystrophy (OPMD) Companies
4 SIGHTS BY PRODUCT
4.1 Overview
4.1.1 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size Markets, 2021 & 2028
4.1.2 Tablets
4.1.3 Capsules
4.1.4 Injectable
4.1.5 Other
4.2 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue & Forecasts
4.2.1 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2017-2022
4.2.2 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2023-2028
4.2.3 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2017-2028
4.3 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales & Forecasts
4.3.1 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2017-2022
4.3.2 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2023-2028
4.3.3 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2017-2028
4.4 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Price (Manufacturers Selling Prices), 2017-2028
5 SIGHTS BY APPLICATION
5.1 Overview
5.1.1 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2021 & 2028
5.1.2 Hospital Pharmacies
5.1.3 Retail Pharmacies
5.1.4 Online Pharmacies
5.2 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue & Forecasts
5.2.1 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2017-2022
5.2.2 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2023-2028
5.2.3 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2017-2028
5.3 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales & Forecasts
5.3.1 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2017-2022
5.3.2 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2023-2028
5.3.3 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2017-2028
5.4 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Price (Manufacturers Selling Prices), 2017-2028
6 SIGHTS BY REGION
6.1 By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2021 & 2028
6.2 By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue & Forecasts
6.2.1 By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2017-2022
6.2.2 By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2023-2028
6.2.3 By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2017-2028
6.3 By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales & Forecasts
6.3.1 By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2017-2022
6.3.2 By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2023-2028
6.3.3 By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2017-2028
6.4 North America
6.4.1 By Country - North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2017-2028
6.4.2 By Country - North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2017-2028
6.4.3 US Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.4.4 Canada Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.4.5 Mexico Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.5 Europe
6.5.1 By Country - Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2017-2028
6.5.2 By Country - Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2017-2028
6.5.3 Germany Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.5.4 France Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.5.5 U.K. Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.5.6 Italy Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.5.7 Russia Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.5.8 Nordic Countries Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.5.9 Benelux Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.6 Asia
6.6.1 By Region - Asia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2017-2028
6.6.2 By Region - Asia Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2017-2028
6.6.3 China Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.6.4 Japan Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.6.5 South Korea Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.6.6 Southeast Asia Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.6.7 India Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.7 South America
6.7.1 By Country - South America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2017-2028
6.7.2 By Country - South America Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2017-2028
6.7.3 Brazil Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.7.4 Argentina Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2017-2028
6.8.2 By Country - Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2017-2028
6.8.3 Turkey Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.8.4 Israel Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.8.5 Saudi Arabia Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.8.6 UAE Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
7 MANUFACTURERS & BRANDS PROFILES
7.1 Benitec Biopharma Inc.
7.1.1 Benitec Biopharma Inc. Corporate Summary
7.1.2 Benitec Biopharma Inc. Business Overview
7.1.3 Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.1.4 Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.1.5 Benitec Biopharma Inc. Key News
7.2 Bioblast Pharma
7.2.1 Bioblast Pharma Corporate Summary
7.2.2 Bioblast Pharma Business Overview
7.2.3 Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.2.4 Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.2.5 Bioblast Pharma Key News
7.3 BioMarin
7.3.1 BioMarin Corporate Summary
7.3.2 BioMarin Business Overview
7.3.3 BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.3.4 BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.3.5 BioMarin Key News
7.4 PTC Therapeutics
7.4.1 PTC Therapeutics Corporate Summary
7.4.2 PTC Therapeutics Business Overview
7.4.3 PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.4.4 PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.4.5 PTC Therapeutics Key News
7.5 NS Pharma
7.5.1 NS Pharma Corporate Summary
7.5.2 NS Pharma Business Overview
7.5.3 NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.5.4 NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.5.5 NS Pharma Key News
7.6 Nobelpharma Co., Ltd
7.6.1 Nobelpharma Co., Ltd Corporate Summary
7.6.2 Nobelpharma Co., Ltd Business Overview
7.6.3 Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.6.4 Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.6.5 Nobelpharma Co., Ltd Key News
7.7 Santhera Pharmaceuticals
7.7.1 Santhera Pharmaceuticals Corporate Summary
7.7.2 Santhera Pharmaceuticals Business Overview
7.7.3 Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.7.4 Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.7.5 Santhera Pharmaceuticals Key News
7.8 Pfizer Inc.
7.8.1 Pfizer Inc. Corporate Summary
7.8.2 Pfizer Inc. Business Overview
7.8.3 Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.8.4 Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.8.5 Pfizer Inc. Key News
7.9 Marathon Pharmaceuticals
7.9.1 Marathon Pharmaceuticals Corporate Summary
7.9.2 Marathon Pharmaceuticals Business Overview
7.9.3 Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.9.4 Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.9.5 Marathon Pharmaceuticals Key News
7.10 Fibrogen
7.10.1 Fibrogen Corporate Summary
7.10.2 Fibrogen Business Overview
7.10.3 Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.10.4 Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.10.5 Fibrogen Key News
7.11 Bristol-Myers Squibb
7.11.1 Bristol-Myers Squibb Corporate Summary
7.11.2 Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Business Overview
7.11.3 Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.11.4 Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.11.5 Bristol-Myers Squibb Key News
7.12 Sarepta Therapeutics
7.12.1 Sarepta Therapeutics Corporate Summary
7.12.2 Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Business Overview
7.12.3 Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.12.4 Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.12.5 Sarepta Therapeutics Key News
7.13 GSK
7.13.1 GSK Corporate Summary
7.13.2 GSK Oculopharyngeal Muscular Dystrophy (OPMD) Business Overview
7.13.3 GSK Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.13.4 GSK Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.13.5 GSK Key News
8 GLOBAL OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD) PRODUCTION CAPACITY, ANALYSIS
8.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Production Capacity, 2017-2028
8.2 Oculopharyngeal Muscular Dystrophy (OPMD) Production Capacity of Key Manufacturers in Global Market
8.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Production by Region
9 KEY MARKET TRENDS, OPPORTUNITY, DRIVERS AND RESTRAINTS
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD) SUPPLY CHAIN ANALYSIS
10.1 Oculopharyngeal Muscular Dystrophy (OPMD) Industry Value Chain
10.2 Oculopharyngeal Muscular Dystrophy (OPMD) Upstream Market
10.3 Oculopharyngeal Muscular Dystrophy (OPMD) Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Oculopharyngeal Muscular Dystrophy (OPMD) Distributors and Sales Agents in Global
11 CONCLUSION
12 APPENDIX
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
1.1 Oculopharyngeal Muscular Dystrophy (OPMD) Market Definition
1.2 Market Segments
1.2.1 Market By Type
1.2.2 Market By Application
1.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 GLOBAL OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD) OVERALL MARKET SIZE
2.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size: 2021 VS 2028
2.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, Prospects & Forecasts: 2017-2028
2.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales: 2017-2028
3 COMPANY LANDSCAPE
3.1 Top Oculopharyngeal Muscular Dystrophy (OPMD) Players in Global Market
3.2 Top Global Oculopharyngeal Muscular Dystrophy (OPMD) Companies Ranked by Revenue
3.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Companies
3.4 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Companies
3.5 Global Oculopharyngeal Muscular Dystrophy (OPMD) Price by Manufacturer (2017-2022)
3.6 Top 3 and Top 5 Oculopharyngeal Muscular Dystrophy (OPMD) Companies in Global Market, by Revenue in 2021
3.7 Global Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Product Type
3.8 Tier 1, Tier 2 and Tier 3 Oculopharyngeal Muscular Dystrophy (OPMD) Players in Global Market
3.8.1 List of Global Tier 1 Oculopharyngeal Muscular Dystrophy (OPMD) Companies
3.8.2 List of Global Tier 2 and Tier 3 Oculopharyngeal Muscular Dystrophy (OPMD) Companies
4 SIGHTS BY PRODUCT
4.1 Overview
4.1.1 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size Markets, 2021 & 2028
4.1.2 Tablets
4.1.3 Capsules
4.1.4 Injectable
4.1.5 Other
4.2 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue & Forecasts
4.2.1 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2017-2022
4.2.2 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2023-2028
4.2.3 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2017-2028
4.3 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales & Forecasts
4.3.1 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2017-2022
4.3.2 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2023-2028
4.3.3 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2017-2028
4.4 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Price (Manufacturers Selling Prices), 2017-2028
5 SIGHTS BY APPLICATION
5.1 Overview
5.1.1 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2021 & 2028
5.1.2 Hospital Pharmacies
5.1.3 Retail Pharmacies
5.1.4 Online Pharmacies
5.2 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue & Forecasts
5.2.1 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2017-2022
5.2.2 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2023-2028
5.2.3 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2017-2028
5.3 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales & Forecasts
5.3.1 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2017-2022
5.3.2 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2023-2028
5.3.3 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2017-2028
5.4 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Price (Manufacturers Selling Prices), 2017-2028
6 SIGHTS BY REGION
6.1 By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2021 & 2028
6.2 By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue & Forecasts
6.2.1 By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2017-2022
6.2.2 By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2023-2028
6.2.3 By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2017-2028
6.3 By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales & Forecasts
6.3.1 By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2017-2022
6.3.2 By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2023-2028
6.3.3 By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2017-2028
6.4 North America
6.4.1 By Country - North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2017-2028
6.4.2 By Country - North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2017-2028
6.4.3 US Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.4.4 Canada Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.4.5 Mexico Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.5 Europe
6.5.1 By Country - Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2017-2028
6.5.2 By Country - Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2017-2028
6.5.3 Germany Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.5.4 France Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.5.5 U.K. Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.5.6 Italy Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.5.7 Russia Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.5.8 Nordic Countries Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.5.9 Benelux Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.6 Asia
6.6.1 By Region - Asia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2017-2028
6.6.2 By Region - Asia Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2017-2028
6.6.3 China Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.6.4 Japan Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.6.5 South Korea Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.6.6 Southeast Asia Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.6.7 India Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.7 South America
6.7.1 By Country - South America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2017-2028
6.7.2 By Country - South America Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2017-2028
6.7.3 Brazil Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.7.4 Argentina Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2017-2028
6.8.2 By Country - Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2017-2028
6.8.3 Turkey Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.8.4 Israel Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.8.5 Saudi Arabia Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.8.6 UAE Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
7 MANUFACTURERS & BRANDS PROFILES
7.1 Benitec Biopharma Inc.
7.1.1 Benitec Biopharma Inc. Corporate Summary
7.1.2 Benitec Biopharma Inc. Business Overview
7.1.3 Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.1.4 Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.1.5 Benitec Biopharma Inc. Key News
7.2 Bioblast Pharma
7.2.1 Bioblast Pharma Corporate Summary
7.2.2 Bioblast Pharma Business Overview
7.2.3 Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.2.4 Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.2.5 Bioblast Pharma Key News
7.3 BioMarin
7.3.1 BioMarin Corporate Summary
7.3.2 BioMarin Business Overview
7.3.3 BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.3.4 BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.3.5 BioMarin Key News
7.4 PTC Therapeutics
7.4.1 PTC Therapeutics Corporate Summary
7.4.2 PTC Therapeutics Business Overview
7.4.3 PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.4.4 PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.4.5 PTC Therapeutics Key News
7.5 NS Pharma
7.5.1 NS Pharma Corporate Summary
7.5.2 NS Pharma Business Overview
7.5.3 NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.5.4 NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.5.5 NS Pharma Key News
7.6 Nobelpharma Co., Ltd
7.6.1 Nobelpharma Co., Ltd Corporate Summary
7.6.2 Nobelpharma Co., Ltd Business Overview
7.6.3 Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.6.4 Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.6.5 Nobelpharma Co., Ltd Key News
7.7 Santhera Pharmaceuticals
7.7.1 Santhera Pharmaceuticals Corporate Summary
7.7.2 Santhera Pharmaceuticals Business Overview
7.7.3 Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.7.4 Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.7.5 Santhera Pharmaceuticals Key News
7.8 Pfizer Inc.
7.8.1 Pfizer Inc. Corporate Summary
7.8.2 Pfizer Inc. Business Overview
7.8.3 Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.8.4 Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.8.5 Pfizer Inc. Key News
7.9 Marathon Pharmaceuticals
7.9.1 Marathon Pharmaceuticals Corporate Summary
7.9.2 Marathon Pharmaceuticals Business Overview
7.9.3 Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.9.4 Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.9.5 Marathon Pharmaceuticals Key News
7.10 Fibrogen
7.10.1 Fibrogen Corporate Summary
7.10.2 Fibrogen Business Overview
7.10.3 Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.10.4 Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.10.5 Fibrogen Key News
7.11 Bristol-Myers Squibb
7.11.1 Bristol-Myers Squibb Corporate Summary
7.11.2 Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Business Overview
7.11.3 Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.11.4 Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.11.5 Bristol-Myers Squibb Key News
7.12 Sarepta Therapeutics
7.12.1 Sarepta Therapeutics Corporate Summary
7.12.2 Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Business Overview
7.12.3 Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.12.4 Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.12.5 Sarepta Therapeutics Key News
7.13 GSK
7.13.1 GSK Corporate Summary
7.13.2 GSK Oculopharyngeal Muscular Dystrophy (OPMD) Business Overview
7.13.3 GSK Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.13.4 GSK Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.13.5 GSK Key News
8 GLOBAL OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD) PRODUCTION CAPACITY, ANALYSIS
8.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Production Capacity, 2017-2028
8.2 Oculopharyngeal Muscular Dystrophy (OPMD) Production Capacity of Key Manufacturers in Global Market
8.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Production by Region
9 KEY MARKET TRENDS, OPPORTUNITY, DRIVERS AND RESTRAINTS
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD) SUPPLY CHAIN ANALYSIS
10.1 Oculopharyngeal Muscular Dystrophy (OPMD) Industry Value Chain
10.2 Oculopharyngeal Muscular Dystrophy (OPMD) Upstream Market
10.3 Oculopharyngeal Muscular Dystrophy (OPMD) Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Oculopharyngeal Muscular Dystrophy (OPMD) Distributors and Sales Agents in Global
11 CONCLUSION
12 APPENDIX
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES
Table 1. Key Players of Oculopharyngeal Muscular Dystrophy (OPMD) in Global Market
Table 2. Top Oculopharyngeal Muscular Dystrophy (OPMD) Players in Global Market, Ranking by Revenue (2021)
Table 3. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Companies, (US$, Mn), 2017-2022
Table 4. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Share by Companies, 2017-2022
Table 5. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Companies, (K Units), 2017-2022
Table 6. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Share by Companies, 2017-2022
Table 7. Key Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Price (2017-2022) & (US$/Unit)
Table 8. Global Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Product Type
Table 9. List of Global Tier 1 Oculopharyngeal Muscular Dystrophy (OPMD) Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Oculopharyngeal Muscular Dystrophy (OPMD) Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (US$, Mn), 2017-2022
Table 13. By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (US$, Mn), 2023-2028
Table 14. By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), 2017-2022
Table 15. By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), 2023-2028
Table 16. By Application – Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2021 & 2028
Table 17. By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (US$, Mn), 2017-2022
Table 18. By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (US$, Mn), 2023-2028
Table 19. By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), 2017-2022
Table 20. By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), 2023-2028
Table 21. By Region – Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2021 VS 2028
Table 22. By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (US$, Mn), 2017-2022
Table 23. By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (US$, Mn), 2023-2028
Table 24. By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), 2017-2022
Table 25. By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), 2023-2028
Table 26. By Country - North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2022
Table 27. By Country - North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2023-2028
Table 28. By Country - North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2017-2022
Table 29. By Country - North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2023-2028
Table 30. By Country - Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2022
Table 31. By Country - Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2023-2028
Table 32. By Country - Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2017-2022
Table 33. By Country - Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2023-2028
Table 34. By Region - Asia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2022
Table 35. By Region - Asia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2023-2028
Table 36. By Region - Asia Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2017-2022
Table 37. By Region - Asia Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2023-2028
Table 38. By Country - South America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2022
Table 39. By Country - South America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2023-2028
Table 40. By Country - South America Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2017-2022
Table 41. By Country - South America Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2023-2028
Table 42. By Country - Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2022
Table 43. By Country - Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2023-2028
Table 44. By Country - Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2017-2022
Table 45. By Country - Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2023-2028
Table 46. Benitec Biopharma Inc. Corporate Summary
Table 47. Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 48. Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 49. Bioblast Pharma Corporate Summary
Table 50. Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 51. Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 52. BioMarin Corporate Summary
Table 53. BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 54. BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 55. PTC Therapeutics Corporate Summary
Table 56. PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 57. PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 58. NS Pharma Corporate Summary
Table 59. NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 60. NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 61. Nobelpharma Co., Ltd Corporate Summary
Table 62. Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 63. Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 64. Santhera Pharmaceuticals Corporate Summary
Table 65. Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 66. Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 67. Pfizer Inc. Corporate Summary
Table 68. Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 69. Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 70. Marathon Pharmaceuticals Corporate Summary
Table 71. Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 72. Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 73. Fibrogen Corporate Summary
Table 74. Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 75. Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 76. Bristol-Myers Squibb Corporate Summary
Table 77. Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 78. Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 79. Sarepta Therapeutics Corporate Summary
Table 80. Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 81. Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 82. GSK Corporate Summary
Table 83. GSK Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 84. GSK Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 85. Oculopharyngeal Muscular Dystrophy (OPMD) Production Capacity (K Units) of Key Manufacturers in Global Market, 2020-2022 (K Units)
Table 86. Global Oculopharyngeal Muscular Dystrophy (OPMD) Capacity Market Share of Key Manufacturers, 2020-2022
Table 87. Global Oculopharyngeal Muscular Dystrophy (OPMD) Production by Region, 2017-2022 (K Units)
Table 88. Global Oculopharyngeal Muscular Dystrophy (OPMD) Production by Region, 2023-2028 (K Units)
Table 89. Oculopharyngeal Muscular Dystrophy (OPMD) Market Opportunities & Trends in Global Market
Table 90. Oculopharyngeal Muscular Dystrophy (OPMD) Market Drivers in Global Market
Table 91. Oculopharyngeal Muscular Dystrophy (OPMD) Market Restraints in Global Market
Table 92. Oculopharyngeal Muscular Dystrophy (OPMD) Raw Materials
Table 93. Oculopharyngeal Muscular Dystrophy (OPMD) Raw Materials Suppliers in Global Market
Table 94. Typical Oculopharyngeal Muscular Dystrophy (OPMD) Downstream
Table 95. Oculopharyngeal Muscular Dystrophy (OPMD) Downstream Clients in Global Market
Table 96. Oculopharyngeal Muscular Dystrophy (OPMD) Distributors and Sales Agents in Global Market
Table 1. Key Players of Oculopharyngeal Muscular Dystrophy (OPMD) in Global Market
Table 2. Top Oculopharyngeal Muscular Dystrophy (OPMD) Players in Global Market, Ranking by Revenue (2021)
Table 3. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Companies, (US$, Mn), 2017-2022
Table 4. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Share by Companies, 2017-2022
Table 5. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Companies, (K Units), 2017-2022
Table 6. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Share by Companies, 2017-2022
Table 7. Key Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Price (2017-2022) & (US$/Unit)
Table 8. Global Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Product Type
Table 9. List of Global Tier 1 Oculopharyngeal Muscular Dystrophy (OPMD) Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Oculopharyngeal Muscular Dystrophy (OPMD) Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (US$, Mn), 2017-2022
Table 13. By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (US$, Mn), 2023-2028
Table 14. By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), 2017-2022
Table 15. By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), 2023-2028
Table 16. By Application – Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2021 & 2028
Table 17. By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (US$, Mn), 2017-2022
Table 18. By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (US$, Mn), 2023-2028
Table 19. By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), 2017-2022
Table 20. By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), 2023-2028
Table 21. By Region – Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2021 VS 2028
Table 22. By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (US$, Mn), 2017-2022
Table 23. By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (US$, Mn), 2023-2028
Table 24. By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), 2017-2022
Table 25. By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), 2023-2028
Table 26. By Country - North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2022
Table 27. By Country - North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2023-2028
Table 28. By Country - North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2017-2022
Table 29. By Country - North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2023-2028
Table 30. By Country - Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2022
Table 31. By Country - Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2023-2028
Table 32. By Country - Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2017-2022
Table 33. By Country - Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2023-2028
Table 34. By Region - Asia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2022
Table 35. By Region - Asia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2023-2028
Table 36. By Region - Asia Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2017-2022
Table 37. By Region - Asia Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2023-2028
Table 38. By Country - South America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2022
Table 39. By Country - South America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2023-2028
Table 40. By Country - South America Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2017-2022
Table 41. By Country - South America Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2023-2028
Table 42. By Country - Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2022
Table 43. By Country - Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2023-2028
Table 44. By Country - Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2017-2022
Table 45. By Country - Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2023-2028
Table 46. Benitec Biopharma Inc. Corporate Summary
Table 47. Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 48. Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 49. Bioblast Pharma Corporate Summary
Table 50. Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 51. Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 52. BioMarin Corporate Summary
Table 53. BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 54. BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 55. PTC Therapeutics Corporate Summary
Table 56. PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 57. PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 58. NS Pharma Corporate Summary
Table 59. NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 60. NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 61. Nobelpharma Co., Ltd Corporate Summary
Table 62. Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 63. Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 64. Santhera Pharmaceuticals Corporate Summary
Table 65. Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 66. Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 67. Pfizer Inc. Corporate Summary
Table 68. Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 69. Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 70. Marathon Pharmaceuticals Corporate Summary
Table 71. Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 72. Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 73. Fibrogen Corporate Summary
Table 74. Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 75. Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 76. Bristol-Myers Squibb Corporate Summary
Table 77. Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 78. Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 79. Sarepta Therapeutics Corporate Summary
Table 80. Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 81. Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 82. GSK Corporate Summary
Table 83. GSK Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 84. GSK Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2017-2022)
Table 85. Oculopharyngeal Muscular Dystrophy (OPMD) Production Capacity (K Units) of Key Manufacturers in Global Market, 2020-2022 (K Units)
Table 86. Global Oculopharyngeal Muscular Dystrophy (OPMD) Capacity Market Share of Key Manufacturers, 2020-2022
Table 87. Global Oculopharyngeal Muscular Dystrophy (OPMD) Production by Region, 2017-2022 (K Units)
Table 88. Global Oculopharyngeal Muscular Dystrophy (OPMD) Production by Region, 2023-2028 (K Units)
Table 89. Oculopharyngeal Muscular Dystrophy (OPMD) Market Opportunities & Trends in Global Market
Table 90. Oculopharyngeal Muscular Dystrophy (OPMD) Market Drivers in Global Market
Table 91. Oculopharyngeal Muscular Dystrophy (OPMD) Market Restraints in Global Market
Table 92. Oculopharyngeal Muscular Dystrophy (OPMD) Raw Materials
Table 93. Oculopharyngeal Muscular Dystrophy (OPMD) Raw Materials Suppliers in Global Market
Table 94. Typical Oculopharyngeal Muscular Dystrophy (OPMD) Downstream
Table 95. Oculopharyngeal Muscular Dystrophy (OPMD) Downstream Clients in Global Market
Table 96. Oculopharyngeal Muscular Dystrophy (OPMD) Distributors and Sales Agents in Global Market
LIST OF FIGURES
Figure 1. Oculopharyngeal Muscular Dystrophy (OPMD) Segment By Type
Figure 2. Oculopharyngeal Muscular Dystrophy (OPMD) Segment By Application
Figure 3. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2017-2028 (US$, Mn)
Figure 7. Oculopharyngeal Muscular Dystrophy (OPMD) Sales in Global Market: 2017-2028 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Oculopharyngeal Muscular Dystrophy (OPMD) Revenue in 2021
Figure 9. By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2017-2028
Figure 10. By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2017-2028
Figure 11. By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Price (US$/Unit), 2017-2028
Figure 12. By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2017-2028
Figure 13. By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2017-2028
Figure 14. By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Price (US$/Unit), 2017-2028
Figure 15. By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2017-2028
Figure 16. By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2017-2028
Figure 17. By Country - North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2017-2028
Figure 18. By Country - North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2017-2028
Figure 19. US Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 20. Canada Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 21. Mexico Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 22. By Country - Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2017-2028
Figure 23. By Country - Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2017-2028
Figure 24. Germany Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 25. France Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 26. U.K. Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 27. Italy Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 28. Russia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 29. Nordic Countries Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 30. Benelux Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 31. By Region - Asia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2017-2028
Figure 32. By Region - Asia Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2017-2028
Figure 33. China Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 34. Japan Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 35. South Korea Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 36. Southeast Asia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 37. India Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 38. By Country - South America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2017-2028
Figure 39. By Country - South America Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2017-2028
Figure 40. Brazil Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 41. Argentina Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 42. By Country - Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2017-2028
Figure 43. By Country - Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2017-2028
Figure 44. Turkey Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 45. Israel Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 46. Saudi Arabia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 47. UAE Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 48. Global Oculopharyngeal Muscular Dystrophy (OPMD) Production Capacity (K Units), 2017-2028
Figure 49. The Percentage of Production Oculopharyngeal Muscular Dystrophy (OPMD) by Region, 2021 VS 2028
Figure 50. Oculopharyngeal Muscular Dystrophy (OPMD) Industry Value Chain
Figure 51. Marketing Channels
Figure 1. Oculopharyngeal Muscular Dystrophy (OPMD) Segment By Type
Figure 2. Oculopharyngeal Muscular Dystrophy (OPMD) Segment By Application
Figure 3. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2017-2028 (US$, Mn)
Figure 7. Oculopharyngeal Muscular Dystrophy (OPMD) Sales in Global Market: 2017-2028 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Oculopharyngeal Muscular Dystrophy (OPMD) Revenue in 2021
Figure 9. By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2017-2028
Figure 10. By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2017-2028
Figure 11. By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Price (US$/Unit), 2017-2028
Figure 12. By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2017-2028
Figure 13. By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2017-2028
Figure 14. By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Price (US$/Unit), 2017-2028
Figure 15. By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2017-2028
Figure 16. By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2017-2028
Figure 17. By Country - North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2017-2028
Figure 18. By Country - North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2017-2028
Figure 19. US Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 20. Canada Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 21. Mexico Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 22. By Country - Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2017-2028
Figure 23. By Country - Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2017-2028
Figure 24. Germany Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 25. France Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 26. U.K. Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 27. Italy Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 28. Russia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 29. Nordic Countries Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 30. Benelux Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 31. By Region - Asia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2017-2028
Figure 32. By Region - Asia Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2017-2028
Figure 33. China Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 34. Japan Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 35. South Korea Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 36. Southeast Asia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 37. India Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 38. By Country - South America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2017-2028
Figure 39. By Country - South America Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2017-2028
Figure 40. Brazil Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 41. Argentina Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 42. By Country - Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2017-2028
Figure 43. By Country - Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2017-2028
Figure 44. Turkey Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 45. Israel Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 46. Saudi Arabia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 47. UAE Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2017-2028
Figure 48. Global Oculopharyngeal Muscular Dystrophy (OPMD) Production Capacity (K Units), 2017-2028
Figure 49. The Percentage of Production Oculopharyngeal Muscular Dystrophy (OPMD) by Region, 2021 VS 2028
Figure 50. Oculopharyngeal Muscular Dystrophy (OPMD) Industry Value Chain
Figure 51. Marketing Channels
